Targeting Disease with Precision: A Primer on Antibody Discovery
The earliest reference to the potential of antibodies for treatment in humans came from an 1890...
BioStrand Omics Analysis Blog:
Drug Development
Exploring the microbiome's impact on immunotherapy efficacy
In our previous blog post (check it out here), we explored how the microbiota can have a profound...
The microbiome- immune axis: the intersection of science and medicine
Hippocrates was quoted as saying ‘all disease starts in the gut’ and over 2000 years later...
LENSai™ - biotherapeutic intelligence for precision drug development
The completion of the Human Genome Project in 2003 set the stage for the modern era in precision...
Creating an AI-ready data foundation for successful AI-enabled drug discovery
Over the past year, we have looked at drug discovery and development from several different...
Computational biology and drug discovery: what to expect in 2023
The year 2022 in computational biology was largely marked by two main advancements:
Our most widely read blogs from 2022
It’s been another momentous year for the global life sciences industry. Ever since the pandemic...
Notes from BioTechX 2022
I recently had the privilege of representing the BioStrand Team at BioTechX, Europe’s largest...
Precision drugs for the precision medicine era
Currently, chemotherapy, using cytotoxic small molecules to kill cancer cells, is the predominant...
Explained: how to plot the prediction quality metrics with AlphaFold2
In a previous blog post, we discussed the importance of AlphaFold2 (as well as other, deep-learning...
A brief retrospective on our second blogiversary
It’s been an eventful two years, to the month, since we launched our omics and analysis blog. Our...